Thus, inhibition of HOXB3-CDCA3/DNMT3B signaling pathway might improve treatment outcomes in AML patients through restoring the expression of miR-375, such as by clinically applicable nanoparticles packaged with miR-375 mimic oligo. This evidence concerns the gene HOXB3 and acute myeloid leukemia.